Reviewing Mediwound (MDWD) & Tilray (TLRY)

Mediwound (NASDAQ:MDWD) and Tilray (NASDAQ:TLRY) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.


This table compares Mediwound and Tilray’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mediwound -783.30% -210.90% -33.92%
Tilray N/A N/A N/A

Insider and Institutional Ownership

32.1% of Mediwound shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Mediwound and Tilray’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mediwound $2.50 million 70.22 -$22.14 million ($0.62) -10.47
Tilray N/A N/A N/A N/A N/A

Tilray has lower revenue, but higher earnings than Mediwound.

Analyst Recommendations

This is a summary of current ratings and price targets for Mediwound and Tilray, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mediwound 0 0 3 0 3.00
Tilray 0 2 1 0 2.33

Mediwound presently has a consensus target price of $11.33, indicating a potential upside of 74.63%. Tilray has a consensus target price of $34.50, indicating a potential downside of 76.52%. Given Mediwound’s stronger consensus rating and higher probable upside, analysts plainly believe Mediwound is more favorable than Tilray.


Mediwound beats Tilray on 5 of the 8 factors compared between the two stocks.

About Mediwound

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

About Tilray

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. was incorporated in 2018 and is headquartered in Nanaimo, Canada.

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with's FREE daily email newsletter.

Leave a Reply